Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE ON PROMISING ANTI-TUMOR ACTIVITY OF NOVEL FGFR2B TARGETING ADC WITH SITE-SPECIFIC CONJUGATED TOPO I INHIBITOR PAYLOAD IN PRECLINICAL TUMOR MODELS AT AACR 2025

This announcement is made by Transcenta Holding Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meaning ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the "**Board**") is pleased to announce the late-breaking presentation of preclinical study results of novel humanized FGFR2b antibody based ADC (TST105) at the AACR Annual Meeting 2025 (AACR 2025). The aforementioned ADC, with a novel topoisomerase I inhibitor payload utilizing glycosyltransferase mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models.

Fibroblast growth factor receptor 2 IIIb (FGFR2b), one of the four members of FGFR family that encode transmembrane receptor tyrosine kinases, is overexpressed in a variety of cancers, such as gastric/GEJ (29%)[1], esophageal (41%)[2], squamous NSCLC (31%)[3], TNBC (13%)[3], ovarian (40%)[3], endometrial (86%)[4], cervical (80%)[4], colorectal (62%)[5], and cholangiocarcinoma (22%)[3].

Significant internalization, specific killing activity and bystander killing effect were observed in vitro. TST105 also shows outstanding in vivo tumor killing efficacy in gastric and colorectal tumor models, which may be contributed by the site-specific conjugation.

In vitro studies demonstrated that TST105 induced specific cytotoxicity to gastric and colorectal tumor cells with a potency between 0.3 nM and 0.4 nM, thus expressing higher potent bystander effect than MMAE based ADCs.

In vivo pharmacology study revealed that TST105 exhibited more potent anti-tumor activity than Bema-MMAE in a gastric tumor model. At 3 mg/kg, the tumor growth inhibition (TGI)% were: TST105 91.25%, Bema-MMAE 48.32% on Day 30. The overall response rate (ORR, 50% reduction of tumor volume from baseline) at 3mg/kg for TST105 was 70%, while the ORR for Bema-MMAE was 0%.

Similarly, in a colorectal cancer model, TST105 induced a better anti-tumor efficacy than 38D4-MMAE. At 5 mg/kg, the tumor growth inhibition (TGI)% were: TST105 57.43%, 38D4-MMAE 1.92% on Day 30.

"We are highly encouraged by the preclinical profile of TST105, our next-generation FGFR2b-targeted ADC, which combines a novel topoisomerase I inhibitor payload with site-specific conjugation technology. The data presented at AACR underscore its transformative potential in addressing cancers with high FGFR2b overexpression." said Dr. Yi Gu, senior vice president of the Company's Research Department, "As we advance TST105 into clinical development, We are committed to translating this promising candidate into a transformative therapy for patients globally."

The AACR 2025 was held from April 25 to April 30, 2025 in Chicago, USA. The AACR Annual Meeting is the critical driver of progress against cancer, being the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

Reference:

[1] Based on the 910 patients screened for potential participation in the FIGHT Phase 2 clinical trial of bemarituzumab.
[2] Yoshino et al Int J Oncol 2007.
[3] Based on IHC staining conducted by Five Prime and Ventana of commercially sourced tissue samples.
[4] Kurban et al Oncol Rep 2004.
[5] Yoshino et al Oncol Rep 2005.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and Chief Executive Officer

Hong Kong, April 30, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.